With insulin resistance playing a major role in the pathogenesis of MetS[13,14], repurposing insulin sensitizers and incretins glucagon-like-peptide-1 receptor (GLP-1R)-agonists has become an accepted therapeutic strategy, particularly at the early stages of the disease[15]. This evidence concerns the gene INS and metabolic syndrome.